Cigarette makers must be worried. A tiny U.S. company has a drug that could all but destroy nicotine addiction in America and beyond, and its shares give investors a chance to profit from this potentially world-changing… Read More

President Obama has given his speech, the Republicans have had their say and the punditry has opined and moved on. Investors should now consider what effect the State of the Union address and the president’s 2010 agenda might have on their portfolios. The speech’s… Read More

Sitting in his college dorm room, a student stared at his jar of coins, wondering what to do with them. Two years later, Jens Molbak started a company that allowed customers the convenience of pouring their change into a machine and getting dollars in return. Read More

A 13% yield — these days or any other — is impressive for any company. Fewer than 50 out of the thousands listed on U.S. exchanges can match that payout. Such a robust yield is a show-stopper on its own,… Read More

It took a talking duck to make one of the largest insurance companies rise from obscurity to one of the most recognized names in the business. Aflac Inc. (NYSE: AFL) provides health insurance for 40 million people worldwide and has received numerous awards for being the best-managed… Read More

The economy, at long last, has begun to recover. That’s not to say things are rosy. Unemployment is still 10%, and some suggest this means the nation’s recovery may be marked by less consumption and higher personal savings than in… Read More

Remember when big banks paid big dividends? Before the financial crisis Citigroup (NYSE: C) paid a quarterly dividend of $0.54; last quarter’s dividend was $0.01. Bank of America (NYSE: BAC) paid a per-share $0.64 quarterly dividend as recently as late 2008; December’s quarterly dividend… Read More

You could take a stab at Medivation, Inc. (Nasdaq: MDVN), whose progress on Alzheimer’s treatment has sent its shares soaring three-fold since March. But then there’s OncoGenix Pharmaceuticals Inc. (Nasdaq: OGXI), whose shares famously fell more than -30% in short order (mostly in one… Read More

The S&P 500 lost ground during the past decade, but this drug maker’s shares returned a gravity-defying +1,179%. That’s the good news. The better news is that the company looks like it’s setting itself up for a repeat performance. Read More

Game on. The market is overreacting to an announcement today from GameStop (NYSE: GME) that it had trouble competing with Wal-Mart (NYSE: WMT) for holiday shoppers. Holiday sales were flat and GameStop lowered its guidance for the year, which ends in March, to between $2.23 to $2.27… Read More